Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

kogklasse Jul. 15 at 3:25 PM

$BMEA Initiated! Good luck to all.

0 · Reply

monstertrades1 Jul. 15 at 2:17 PM

$BMEA strong buy 💪

0 · Reply

monstertrades1 Jul. 15 at 2:03 PM

$BMEA

0 · Reply

oldmanrizzer Jul. 15 at 1:56 PM

$BMEA How about some goddamn volume you turd?

0 · Reply

BioRich Jul. 15 at 1:21 PM

$GUTS Love $GUTS, but sometimes not their biggest fan at how they present things. The data is often much better than how they present it so I took the liberty of cleaning up their slide to remove distraction and it paints the picture we're all hearing and seeing. Hope this helps. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! #FractylForward $XBI $BMY $BIOA $BMEA

1 · Reply

monstertrades1 Jul. 15 at 3:08 AM

$BMEA fresh off press https://x.com/i/status/2077155012648567123

0 · Reply

B34Rhunter Jul. 15 at 1:10 AM

$BMEA 11 weeks until the end of Q3… praying by the end of the year we all see the first leg up of generational wealth 🙏🏻

0 · Reply

HUNTER40 Jul. 15 at 1:01 AM

$BMEA the stock is $1.30 and is a potential cure for diabetes, and people act like the company is worth nothing……you just can’t make that type of idiocy up.

1 · Reply

HUNTER40 Jul. 14 at 11:26 PM

$BMEA one more for the road yeah we a 99M company, after icovamenib pill is discontinued the patients beta cells continue to produce insulin. We a 99M company with 40M+ on the balance sheet in cash.

0 · Reply

HUNTER40 Jul. 14 at 11:21 PM

$BMEA let’s pretend the potential cure for diabetes is a 99M market cap 40M plus which is cash on the balance sheet, as they do the Leicester study for weight loss with $NVO

0 · Reply

Biomea Fusion Transcript: AGM 2026

Jun 5, 2026, 7:32 PM EDT - 5 weeks ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

2026-06-04T19:41:19.000Z - 5 weeks ago

Biomea Fusion management to meet with Citizens

Jun 4, 2026, 8:10 AM EDT - 5 weeks ago

Biomea Fusion Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T14:46:35.000Z - 6 weeks ago

Biomea Fusion partners with University of Leicester on obesity study

Jun 3, 2026, 8:00 AM EDT - 6 weeks ago

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

May 29, 2026, 7:00 AM EDT - 6 weeks ago

Biomea Fusion Slides: Corporate presentation

May 19, 2026, 3:00 PM EDT - 2 months ago

Biomea Fusion Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 4:05 PM EDT - 2 months ago

Biomea Fusion to Participate at Upcoming Investor Conferences

2026-05-11T23:09:08.000Z - 2 months ago

Biomea Fusion reports Q1 EPS (17c), consensus (19c)

May 11, 2026, 4:54 PM EDT - 2 months ago

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

May 11, 2026, 7:00 AM EDT - 2 months ago

Biomea Fusion Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 2 months ago

Biomea Fusion Earnings release: Q1 2026

May 5, 2026, 5:50 PM EDT - 2 months ago

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

May 5, 2026, 2:30 PM EDT - 2 months ago

Biomea Fusion Transcript: Status update

2026-05-05T08:25:12.000Z - 2 months ago

Biomea Fusion initiated with an Outperform at Citizens

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Biomea Fusion Transcript: Study result

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Biomea Fusion Press release: Study result

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Biomea Fusion Slides: Study result

2026-04-27T21:40:11.000Z - 2 months ago

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

Apr 27, 2026, 5:37 PM EDT - 2 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Biomea Fusion Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Slides: Corporate presentation

2026-03-31T11:24:55.000Z - 3 months ago

Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Mar 30, 2026, 3:00 PM EDT - 3 months ago

Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 1:00 PM EDT - 3 months ago

Biomea Fusion Transcript: Fireside chat

2026-03-27T10:32:33.000Z - 3 months ago

Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

Mar 24, 2026, 4:05 PM EDT - 4 months ago

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 24, 2026, 4:00 PM EDT - 4 months ago

Biomea Fusion Annual report: Q4 2025

Mar 24, 2026, 4:00 PM EDT - 4 months ago

Biomea Fusion Earnings release: Q4 2025

2026-03-15T14:50:06.000Z - 4 months ago

Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

Mar 14, 2026, 4:30 AM EDT - 4 months ago

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Mar 10, 2026, 2:50 PM EDT - 4 months ago

Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026

2026-03-04T15:46:54.000Z - 4 months ago

Biomea Fusion management to meet virtually with Craig-Hallum

Feb 26, 2026, 10:00 AM EST - 4 months ago

Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:00 AM EST - 4 months ago

Biomea Fusion Slides: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 7:00 AM EST - 5 months ago

Biomea Fusion Slides: Corporate presentation

Jan 14, 2026, 8:15 PM EST - 6 months ago

Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 6 months ago

Biomea Fusion Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-13T20:20:23.000Z - 6 months ago

Biomea Fusion initiated with a Buy at Rodman & Renshaw

2026-01-12T13:40:46.000Z - 6 months ago

Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones

Jan 12, 2026, 8:00 AM EST - 6 months ago

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Jan 12, 2026, 7:00 AM EST - 6 months ago

Biomea Fusion Slides: Corporate presentation

Dec 17, 2025, 7:00 AM EST - 7 months ago

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-10T01:05:10.000Z - 7 months ago

Biomea Fusion announces KOL presentation

Dec 9, 2025, 6:35 PM EST - 7 months ago

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

2025-12-05T12:10:07.000Z - 7 months ago

Biomea Fusion presents COVALENT-111 study results at WCIRDC

Dec 5, 2025, 7:00 AM EST - 7 months ago

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 3, 2025, 7:30 AM EST - 8 months ago

Biomea Fusion Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 8 months ago

Biomea Fusion Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 4:10 PM EST - 8 months ago

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:05 PM EST - 8 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2025, 7:00 AM EST - 8 months ago

Biomea Fusion Slides: Corporate Presentation

Nov 17, 2025, 11:30 AM EST - 8 months ago

Biomea Fusion Transcript: Jefferies London Healthcare Conference 2025

2025-11-15T15:15:11.000Z - 8 months ago

Biomea Fusion downgraded to Underweight from Neutral at JPMorgan

Nov 10, 2025, 7:00 AM EST - 8 months ago

Biomea Fusion to Participate at Jefferies London Healthcare Conference

2025-11-10T11:35:48.000Z - 8 months ago

Biomea Fusion price target lowered to $6 from $7 at Citi

2025-11-05T12:41:37.000Z - 9 months ago

Biomea Fusion announces presentation of two posters for BMF-650, icovamenib

2025-11-05T12:20:51.000Z - 9 months ago

Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital

Nov 5, 2025, 7:00 AM EST - 9 months ago

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Nov 4, 2025, 4:05 PM EST - 9 months ago

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 4, 2025, 4:00 PM EST - 9 months ago

Biomea Fusion Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Biomea Fusion Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 27, 2025, 8:00 AM EDT - 9 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Oct 23, 2025, 11:00 AM EDT - 9 months ago

Biomea Fusion Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Oct 21, 2025, 7:05 PM EDT - 9 months ago

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Transcript: Study Result

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Press release: Study Result

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Biomea Fusion Slides: Study Result

Oct 7, 2025, 8:00 AM EDT - 10 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 10 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:03 PM EDT - 10 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Oct 1, 2025, 7:00 AM EDT - 10 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 7:00 AM EDT - 10 months ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Registration statement: Registration Filing

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Quarterly report: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jun 23, 2025, 11:00 AM EDT - 1 year ago

Biomea Fusion Slides: Investor Presentation

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 1 year ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 7:28 PM EDT - 1 year ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 1 year ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Quarterly report: Q1 2025

May 5, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biomea Fusion Proxy statement: Proxy Filing

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Annual report: Q4 2024

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Biomea Fusion Earnings release: Q4 2024

Mar 25, 2025, 7:00 PM EDT - 1 year ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 19, 2025, 1:00 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Biomea Fusion Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 12, 2025, 10:40 AM EST - 1 year ago

Biomea Fusion Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: FY 2025

Dec 17, 2024, 8:10 AM EST - 1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Transcript: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Press release: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Slides: Study Result

Dec 16, 2024, 6:15 PM EST - 1 year ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 1 year ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Press release: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Slides: Study Update

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 1 year ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 5, 2024, 7:55 AM EST - 1 year ago

Biomea Fusion Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Biomea Fusion Transcript: Piper Sandler 36th Annual Healthcare Conference

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Press release: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Slides: Status Update

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

kogklasse Jul. 15 at 3:25 PM

$BMEA Initiated! Good luck to all.

0 · Reply

monstertrades1 Jul. 15 at 2:17 PM

$BMEA strong buy 💪

0 · Reply

monstertrades1 Jul. 15 at 2:03 PM

$BMEA

0 · Reply

oldmanrizzer Jul. 15 at 1:56 PM

$BMEA How about some goddamn volume you turd?

0 · Reply

BioRich Jul. 15 at 1:21 PM

1 · Reply

monstertrades1 Jul. 15 at 3:08 AM

$BMEA fresh off press https://x.com/i/status/2077155012648567123

0 · Reply

B34Rhunter Jul. 15 at 1:10 AM

$BMEA 11 weeks until the end of Q3… praying by the end of the year we all see the first leg up of generational wealth 🙏🏻

0 · Reply

HUNTER40 Jul. 15 at 1:01 AM

$BMEA the stock is $1.30 and is a potential cure for diabetes, and people act like the company is worth nothing……you just can’t make that type of idiocy up.

1 · Reply

HUNTER40 Jul. 14 at 11:26 PM

$BMEA one more for the road yeah we a 99M company, after icovamenib pill is discontinued the patients beta cells continue to produce insulin. We a 99M company with 40M+ on the balance sheet in cash.

0 · Reply

HUNTER40 Jul. 14 at 11:21 PM

$BMEA let’s pretend the potential cure for diabetes is a 99M market cap 40M plus which is cash on the balance sheet, as they do the Leicester study for weight loss with $NVO

0 · Reply

B34Rhunter Jul. 14 at 8:01 PM

$BMEA dang the ask was getting stacked at close, somebody wants to keep price down 🧐

1 · Reply

monstertrades1 Jul. 14 at 7:51 PM

$BMEA

0 · Reply

monstertrades1 Jul. 14 at 7:51 PM

$BMEA

0 · Reply

monstertrades1 Jul. 14 at 7:51 PM

$BMEA

0 · Reply

monstertrades1 Jul. 14 at 7:16 PM

$BMEA strong buy!

0 · Reply

Cobre_Miner Jul. 14 at 6:06 PM

$BMEA be wary of thin skinned pseudo longs…🙄😂

1 · Reply

Danzzzzzzzz Jul. 14 at 5:29 PM

$BMEA volumes are so tinny.... Shorts are probably starting to wonder seriously how they can cover 14M shares without bringing the price higher... To my mind, there're several categories of short sellers on biomea: above $20/$30, above $10, above $5, above $3 and above $2. The one between current price(1.3) and $2 are probably starting to worry a little. That is just a beginning. Domino's effect when price will surge again 🤔

1 · Reply

HUNTER40 Jul. 14 at 4:09 PM

$BMEA $1.32 can’t believe this thing is still below $2 it’s in the window and the trial is enrolled.

1 · Reply

monstertrades1 Jul. 14 at 3:28 PM

$BMEA BMF-650 A Next-Generation Oral Small Molecule GLP-1 Receptor Agonist Biomea Fusion is prioritizing the development of BMF-650, an investigational, next-generation, oral small-molecule GLP-1 receptor agonist (GLP-1 RA), which has demonstrated positive, early preclinical activity, including improved glucose-stimulated insulin secretion, reduction in blood glucose concentration, appetite suppression and weight loss in cynomolgus monkeys. BMF-650 is currently being evaluated in a Phase I clinical study in healthy participants. https://biomeafusion.com/pipeline-innovation/

0 · Reply

monstertrades1 Jul. 14 at 3:26 PM

$BMEA Strong buy! @topstockalerts

0 · Reply

ajmrtxl Jul. 14 at 1:43 PM

$BMEA 's latest squeeze play

1 · Reply

HUNTER40 Jul. 14 at 12:41 PM

$BMEA

0 · Reply

Market Cap	96.16M
Revenue (ttm)	0.00
Net Income (ttm)	-61.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	722,100
Avg Vol	1,125,238
Day's Range	N/A - N/A
Shares Out	72.30M
Stochastic %K	29%
Beta	-0.31
Analysts	Strong Sell
Price Target	$7.29